MIMIX
Live / Allowed — Notice of allowance issued (as of 10 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Nov 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98873501
- Mark type
- Stylized text
- Filed
- 26 Nov 2024
- Published for opposition
- 16 Dec 2025
- Attorney of record
- Kevin Oliver
Goods and services
- Class 001 — Chemicals: Biological preparations for laboratory, biopharmaceutical processing, and research purposes, for use as reference standards in science; Biological preparations for cancer research; Biological preparations for quality control of laboratory research; Cell line-derived nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, for use as reference standards for research purpose; Samples made of nucleic acids for use in biochemical or biological laboratory analysis for research purposes; Samples made of formalin and nucleic acids for use in a biochemical or biological laboratory analysis for research purposes; Samples made of formalin and cells for use in a biochemical or biological laboratory analysis for research purposes; Cell line-derived products in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, for scientific and research purposes, including for clinical investigations and for use in product testing; Reference standards in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, used for research purposes, namely, used for next generation sequencing, droplet-digital, Real-Time Polymerase Chain Reaction (PCR) or Sanger sequencing
- Class 005 — Pharmaceuticals: cell line-derived reference standards in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, used in clinical medical samples; Reference standard substances in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, used for clinical tests for medical purposes; medical reference standards in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, used for next generation sequencing, droplet-digital, Real-Time Polymerase Chain Reaction (PCR) or Sanger sequencing; medical reference standards in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, used for detecting chromosomal abnormalities; medical reference standards in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, used for analysing biological samples
- Class 040 — Treatment of materials: Custom manufacture of cell line-delivered products in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids, for medical and commercial applications; Custom manufacture of reference standards in the nature of nucleic acids, formalin-fixed paraffin-embedded (FFPE) cells, formalin-fixed paraffin-embedded (FFPE) nucleic acids, and formalin-compromised nucleic acids
Owner
- Revvity Health Sciences, Inc., Waltham, MA, US
- Revvity Health Sciences, Inc., Waltham, MA, US
Prosecution history
- 10 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Dec 2025 — PUBLISHED FOR OPPOSITION
- 10 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 07 Nov 2025 — ASSIGNED TO EXAMINER
- 26 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 11 Jun 2025 — ASSIGNED TO LIE
- 27 May 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 27 May 2025 — NON-FINAL ACTION E-MAILED
- 27 May 2025 — NON-FINAL ACTION WRITTEN
- 19 May 2025 — ASSIGNED TO EXAMINER
- 26 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED